Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izalontamab - Sichuan Baili Pharmaceutical

Next Previous
Drug Profile

Izalontamab - Sichuan Baili Pharmaceutical

Alternative Names: SI-B001

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Colorectal cancer; Gastric cancer; Squamous cell cancer

Most Recent Events

  • 07 Nov 2024 Phase-II clinical trials in Non-small cell lung cancer (Recurrent, Metastatic disease, First-line therapy, Combination therapy) in China (IV) (NCT06668961)
  • 01 Nov 2024 Sichuan Baili Pharmaceutical plans a phase II trial for Head and Neck Squamous Cell Carcinoma (First-line therapy, Recurrent, Metastatic disease, Combination-therapy) (IV, Infusion), in November 2024 (NCT06668961)
  • 30 Oct 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT05949606)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top